Showing results (331-340 of 426) with videos related to
Sort By:
Pageof 43
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseHamzah Abu-Sbeih, David M Faleck, Biagio Ricciuti, et al.Liver International : Official Journal of the International Association for the Study of the Liver|August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinomaMathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.Hepatology International|April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinomaMathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.Journal of Hepatology|April 3, 2022
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinomaMaryam Barsch, Henrike Salié, Alexandra Emilia Schlaak, et al.Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2022
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancerB Ricciuti, J V Alessi, A Elkrief, et al.Liver Cancer|December 24, 2021
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular CarcinomaPetros Fessas, Muntaha Naeem, Matthias Pinter, et al.JHEP Reports : Innovation in Hepatology|December 1, 2025
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyPasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.Clinical Genitourinary Cancer|January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial CarcinomaRafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.Pageof 43